Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D01LNG
|
|||
Former ID |
DCL000714
|
|||
Drug Name |
Balicatib
|
|||
Synonyms |
N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Osteoporosis [ICD-11: FB83.0; ICD-10: M85.8] | Discontinued in Phase 2 | [1], [2] | |
Company |
Novartis
|
|||
Structure |
Download2D MOL |
|||
Formula |
C23H33N5O2
|
|||
Canonical SMILES |
CCCN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3(CCCCC3)C(=O)NCC#N
|
|||
InChI |
1S/C23H33N5O2/c1-2-14-27-15-17-28(18-16-27)20-8-6-19(7-9-20)21(29)26-23(10-4-3-5-11-23)22(30)25-13-12-24/h6-9H,2-5,10-11,13-18H2,1H3,(H,25,30)(H,26,29)
|
|||
InChIKey |
LLCRBOWRJOUJAE-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 354813-19-7
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Cathepsin K (CTSK) | Target Info | Inhibitor | [2] |
KEGG Pathway | Lysosome | |||
Osteoclast differentiation | ||||
Toll-like receptor signaling pathway | ||||
Rheumatoid arthritis | ||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
RANKL Signaling Pathway | ||||
IL2 Signaling Pathway | ||||
Reactome | Collagen degradation | |||
Degradation of the extracellular matrix | ||||
Activation of Matrix Metalloproteinases | ||||
Trafficking and processing of endosomal TLR | ||||
MHC class II antigen presentation | ||||
WikiPathways | RANKL/RANK Signaling Pathway | |||
Osteoclast Signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7861). | |||
REF 2 | Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.